BOOST II Trial

Management of severe TBI informed by multimodal ICP and PbtO2 monitoring reduced brain tissue hypoxia with a trend towards lower mortality and more favorable outcomes than ICP-only treatment. A Phase III randomized trial to assess impact on neurologic outcome of ICP plus PbtO2-directed treatment of severe TBI is warranted1.

Referenzen